FindTrial
Sign In

Gene mutations in Indian patients with prostate cancer

Prevalence of Mutations Influencing Prostate Cancer Risk and Progression

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/05/042780
Enrollment
300
Registered
2022-05-24
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C61- Malignant neoplasm of prostate

Interventions

None listed

Sponsors

University of Tornto
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with metastatic prostate cancer Willing to participate

Exclusion criteria

Exclusion criteria: Localised prostate cancer

Design outcomes

Primary

MeasureTime frame
Prevalence of gremlin mutation in patients with metastatic prostate cancerTimepoint: 4 weeks—

Secondary

MeasureTime frame
Prevalence of BRCA2 mutation in patients with metastatic prostate cancerTimepoint: 4 weeks—

Countries

India

Contacts

Public ContactAtul Batra

AIIMS, New Delhi

batraatul85@gmail.com01129575043

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026